The company said it has acquired 100 per cent equity stake in Laboratorios Grin, Mexico.
US-based pharma giants Eli Lilly and company has filed a case against two Indian drug makers, Aurobindo Pharma and Lupin alleging infringement of patent of its anti-depressant drug Cymbalta.
Check out some of the stocks that will react on the basis of their numbers in the near term.
Lupin was bound downward today after the company announced an 83.6% drop in net profit for Q4.
There is a need to incentivise R&D investments, offer corporate tax concessions and establish an effective intellectual property rights regime in order to push the growth of domestic pharmaceutical industry, as per the industry bodies. Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.
Pharma company Lupin is looking at acquisitions abroad for its expansion plans this fiscal and has raised $100 million for the purpose.
Lupin Pharmaceuticals Inc, the wholly owned subsidiary of Lupin, has entered into an alliance with Cornerstone BioPharma Inc.
The company has received final approval from the US Food and Drug Administration for its Abacavir Sulfate Lamivudine, and Zidovudine Tablets, Lupin Ltd said in a statement.
Leading pharmaceutical company Lupin Ltd on Wednesday said it was looking at acquiring companies and brands in a bid to strengthen its paediatric business in the US market.
Lupin Pharmaceuticals Inc, a wholly owned subsidiary of Mumbai-based Lupin Ltd, has forayed into the US pediatric segment by inking an agreement with Allergan Inc to promote 'Zymar' in that country.
Pfizer, the world's largest pharmaceutical company, has filed patent infringement suits against Sun Pharma, Wockhardt Ltd and Lupin Ltd to prevent these companies from securing marketing approvals for the generic equivalents of its high-selling neuropathic pain management drug Lyrica in the United States.
Lupin Ltd received US Food & Drug Administration's approval for its abbreviated new drug application for Cefuroxime Axetil tablets.
Lupin Ltd will set up a Rs 100-million plant for manufacturing Lovastatin, a cholesterol lowering active pharmaceutical ingredient, at the company's facilities in Tarapur, Maharashtra.
The company has received final approval for its supplemental New Drug Application (sNDA) for Antara (Fenofibrate) capsules in 30 mg and 90 mg strengths from the United States Food and Drug Administration (USFDA), Lupin Ltd said in a statement.
This acquisition marks Lupin's foray into the Japanese branded market in-line with aspirations to build business globally.
The pact would entail the Indian company receiving up to $38 million (over Rs 165 crore).
Pharmaceutical company, Lupin has sold certain patent applications and other related intellectual property for Perindopril (hypertension drug) for multiple countries to French firm Laboratories Servier for Rs 115.31 crore (Euro 20 million).
The company has received a tentative approval for the company's abbreviated new drug application for Eszopiclone tablets from the US Food and Drug Administration, Lupin said in a filing to the Bombay Stock Exchange.
In a twist to the tale of drug patent infringement cases in the United States, Indian drug company Lupin has sued Ranbaxy Laboratories, which is now controlled by Japanese drug major Daiichi Sankyo, in an American court.
The US Court of Appeals for the Federal Circuit has ruled in the company's favour regarding its appeal of a previous judgement by a lower court for Bayer AG's Yaz oral contraceptive product.
Lupin Ltd commissioned its facility at Mandideep near Bhopal, Madhya Pradesh, to manufacture Lisinopril, an active pharmaceutical ingredient in the cardiovascutar segment with a capacity of 12MT per annum.
Drug maker Lupin Ltd on Thursday said it would acquire 51 per cent stake in Belgium-based Artifex Finance CVA for an undisclosed sum.
From zero revenues eight years ago, Lupin has posted Rs 621 crore (Rs 6.21 billion) in sales last year-that too in a country regarded as one of the toughest markets in the world for generics.
Teva Women's Health filed a suit this week in the US District Court for New Jersey, claiming that Lupin had filed an abbreviated new drug application with the US Food and Drug Administration, which infringes the patents of Seasonale, its oral contraceptive that limits the number of menstrual periods women have in a year.
Lupin Ltd said it currently has no plans to raise money from any investor.
Drugmaker Lupin Ltd said on Monday it has signed a licensing agreement with leading Italian pharmaceutical company ItalFarmaco for marketing its cardiovascular critical care product in the Indian market.
The Melbourne-headquartered Generic Health markets generic prescription and over-the-counter products in the Australian market, in a partnership model with established global generic drug makers. The company sells approximately $500 million (nearly Rs 2,150 crore) worth of drugs in Australia, which has Rs 11,300 crore (A$3 billion) worth generics market. The total drug market in Australia is worth A$10 billion (Rs37,800 crore).
South Africa's largest generic drug company Enaleni Pharmaceuticals is planning to sue Lupin - the Rs 1,200 crore (Rs 12 billion) domestic pharma major - for terminating a marketing right unilaterally in violation of an existing agreement.
The recent recalls come amid increased FDA scrutiny of medicines produced in India.
Lupin Ltd, one of the top five domestic pharmaceutical companies, plans to revamp its drug research programme and foray into novel biotech and reverse engineering of biotech drugs (or biosimilars).
Mumbai-based pharma major Lupin will invest over Rs 200 crore (Rs 2 billion) this year to create additional manufacturing capacities.
While domestic sales in the second quarter are expected to be weak for major players, Lupin is likely to outperform the pharma sector on the back of a growing chronic portfolio.
Lupin Ltd is considering to set up its own marketing force in the United States even as the pharma major is to create a global advisory board as part of its corporate governance initiative.\n\n\n\n
The Mumbai-based firm said it has signed an pact with the Department of Health, Government of Brazil and Farmanguinhos, the largest public sector undertaking in health care in Brazil, to supply the drug.
Lupin Ltd on Thursday said it has received USFDA approval for its Abbreviated New Drug Application for multiple strengths of antibiotic Cephalexin capsules.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances